Richard is involved in the scientific due diligence, and assessing the technological development and market potential of projects entering into TIAP’s pipeline. He also scouts for new projects from TIAP’s academic member institutions.
Prior to joining TIAP, Richard conducted market research into colorectal cancer, liquid biopsy technologies and epigenetic technologies, among others, as an intern with the diagnostics startup Enrich Bioscience. His other past experiences include research into the human skin microbiome in the context of psoriatic arthritis at the Krembil Research Institute, and administration of clinical trials in oncology at the Princess Margaret Hospital Cancer Centre.
Richard holds a M.Sc. (Applied) in Biotechnology from McGill University in Montreal and a B.Sc. (Honors) in Molecular Genetics and Neuroscience from the University of Toronto.